An overview of screening, treatment, and next steps in research in rheumatoid arthritis interstitial lung disease

Abstract

Rheumatoid arthritis associated interstitial lung disease (RA-ILD) has significant clinical impact on patients due to increased morbidity and mortality. Understanding the progression of ILD in patients with RA from when asymptomatic to clinical progression and the clinical, genetic, and novel markers associated with disease progression is an important step in altering the natural history of ILD in patients with RA. We review the natural history and epidemiology of RA-ILD, with a focus on Latin-American epidemiology in RA-ILD. Additionally, we discuss unique features of RA-ILD compared to other forms of ILD, early disease detection, and current concepts in treatment.